Tau PET Imaging for Alzheimer's Disease
(ABCD2-TAU Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how certain brain changes might relate to aging and the early stages of Alzheimer's Disease. It involves a PET scan, an imaging test, to study brain health in older adults. The trial uses [18F]AV-1451, also known as (18F)Flortaucipir, a radiotracer used in these scans. It specifically targets African American individuals aged 65 and older who are part of an ongoing study and show normal cognitive function. Participants will have already undergone specific brain scans and assessments. By understanding these brain patterns, researchers aim to unlock clues about cognitive decline. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research on brain health and aging.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that this PET/CT method is safe for cognitively normal older adults?
Studies have shown that [18F]AV-1451, also known as Flortaucipir, is generally safe for use in PET scans. Research indicates that this tracer effectively identifies tau protein build-up in the brain, aiding in the study of Alzheimer's disease.
One study found a potential risk, as the tracer affected a heart safety test. However, the safety margin is 42 times higher than the risky level, indicating a very low actual risk.
The FDA has already approved Flortaucipir for certain PET scans, supporting its safety record. So far, significant reports of serious side effects in humans have not emerged. Overall, Flortaucipir is considered well-tolerated.12345Why are researchers excited about this trial?
Researchers are excited about [18F]AV-1451, also known as Flortaucipir, because it offers a new way to visualize tau proteins in the brain using PET/CT imaging. Unlike current treatments for neurodegenerative conditions, which often focus on symptomatic relief, Flortaucipir allows doctors to directly observe tau pathology, which is a hallmark of diseases like Alzheimer's. This imaging could lead to earlier and more accurate diagnoses, potentially transforming how these conditions are managed and treated.
What evidence suggests that this PET/CT method is effective for studying age-related cognitive decline and preclinical Alzheimer's Disease?
Research shows that [18F]Flortaucipir is a promising tool for imaging tau proteins in the brain. Tau proteins can accumulate in conditions like Alzheimer's disease, and early detection aids in understanding memory and thinking problems. Studies have shown that [18F]Flortaucipir accurately identifies these tau deposits. This tracer is recognized for its high accuracy in assessing Alzheimer's and other brain conditions. It enables doctors to observe and track changes in the brain, offering insights into early-stage memory and thinking issues before symptoms emerge.678910
Who Is on the Research Team?
David A Wolk, MD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
PET Imaging
Participants undergo a one-day PET scan using the radiotracer [18F]AV-1451
Follow-up
Participants are monitored annually as part of the ABCD2 study
What Are the Treatments Tested in This Trial?
Interventions
- [18F]AV-1451
- (18F)Flortaucipir
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
PET.CT using the radiotracer \[18F\]AV-1451
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Pennsylvania Department of Health
Collaborator
Citations
Article Improved interpretation of 18 F-florzolotau PET in ...
We developed a normalization-free deep-learning (NFDL) model for 18 F-florzolotau PET, which achieved significantly higher accuracy for both PSP and MSA-P.
Direct Comparison of the Tau PET Tracers 18F-Flortaucipir ...
This study compared 2 frequently used tau PET tracers, 18F-flortaucipir and 18F-MK-6240, in the same subjects. Methods: 18F-flortaucipir and 18F-MK-6240 scans ...
Development and Validation of a 18F-Flortaucipir PET Visual ...
We developed a novel 18 F-flortaucipir PET (FTP, or Tauvid) visual read method enabling stratification of patients with Alzheimer disease (AD) according to the ...
4.
researchgate.net
researchgate.net/figure/QC-Data-for-Process-Verification-Batches-of-18-FAV1451_tbl1_318236558QC Data for Process Verification Batches of [ 18 F]AV1451
In conclusion, [18F]Flortaucipir was reproducibly achieved with desired radiochemical yield and high radiochemical purity and molar activity. Three GMP ...
Parametric Estimation of Reference Signal Intensity for ...
In this study, we evaluated the utility and reliability of the PERSI method for analyzing data from PET imaging using 2 different tau tracers— ...
18F-Flortaucipir (AV1451) imaging identifies grey matter ...
This study aimed (1) to assess the association of imaging evidence of tau pathology with brain volumes in retired athletes and (2) to examine ...
Flortaucipir (18F)
Flortaucipir (18 F), sold under the brand name Tauvid, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging to ...
Tauvid™: The First FDA-Approved PET Tracer for Imaging ...
Tauvid might have a potential cardiotoxicity as it had an IC50 value of 0.610 μM in the in vitro hERG assay. Nevertheless, the safety margin is at least 42-fold ...
Discriminative Accuracy of [ 18 F]flortaucipir Positron ...
The use of [ 18 F]flortaucipir PET had an estimated sensitivity of 89.9% and specificity of 90.6% for Alzheimer disease vs other neurodegenerative diseases.
10.
ejnmmipharmchem.springeropen.com
ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-017-0027-7An updated radiosynthesis of [ 18 F]AV1451 for tau PET imaging
[18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer's disease (AD) and related non-AD tauopathies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.